Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hemodialysis

This article was originally published in The Gray Sheet

Executive Summary

Acute onset of severe neurological symptoms is linked to hemodialysis treatment with aged dialyzers, according to investigators from FDA and the Centers for Disease Control and Prevention. A study published in the April 26 Journal of the American Medical Association shows that seven patients at one hospital developed decreased vision, hearing, conjunctivitis and headache 7-24 hours after hemodialysis on machines that contained aged cellulose acetate membranes of dialyzers, which allowed cellulose acetate degradation products to enter the blood. Dialysis centers have been advised to rotate their stocks of dialyzers, and manufacturers are being asked by FDA to place a date of manufacture on each device. The agency is working with industry to develop standards on the shelf-life of dialyzers to address the problem
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013312

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel